TriSalus Life Sciences (NASDAQ:TLSI) Announces Earnings Results, Hits Estimates

TriSalus Life Sciences (NASDAQ:TLSI) issued its quarterly earnings data on Thursday. The company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16), FiscalAI reports. The business had revenue of $11.41 million during the quarter, compared to analyst estimates of $10.27 million.

Here are the key takeaways from TriSalus Life Sciences’ conference call:

• Q2 revenue reached $11.4 million, up sequentially and 1.7% year over year, while gross margin improved to 86.8% from 83.9% due to lower unit costs and manufacturing improvements.
• CMS issued a new G-code extending TriNav reimbursement into physician office-based labs, broadening access beyond hospitals and ambulatory surgery centers and potentially supporting adoption in liver, uterine, prostate, and genicular embolization.
• TriSalus has 11 active clinical studies across 27 sites involving more than 400 treated patients; additional trials are launching in the second half of 2026, while PETER data has been submitted for peer-reviewed publication and TriNav Advance remains under FDA review.
• Management reiterated 2026 revenue guidance of $54 million to $57 million, representing 19%–26% growth, and expects sequential growth acceleration in the second half as the expanded sales force becomes more productive and first-half expansion costs decline.
• The commercial build-out increased sales and marketing expenses to $11.4 million from $7.2 million, contributing to a wider adjusted EBITDA loss of $7.1 million versus $5.3 million a year earlier, although management said its $46.3 million cash balance funds the strategic plan.

TriSalus Life Sciences Price Performance

TLSI stock traded up $0.74 during midday trading on Friday, reaching $5.61. The company had a trading volume of 700,814 shares, compared to its average volume of 195,434. The company has a market capitalization of $344.57 million, a price-to-earnings ratio of -4.32 and a beta of 0.43. The stock has a 50 day moving average price of $4.17 and a 200-day moving average price of $4.31. TriSalus Life Sciences has a 1-year low of $2.20 and a 1-year high of $7.95. The company has a debt-to-equity ratio of 2.58, a current ratio of 5.78 and a quick ratio of 5.46.

Insider Buying and Selling

In other news, Director Mats Wahlstrom bought 60,000 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $2.53 per share, for a total transaction of $151,800.00. Following the transaction, the director owned 147,555 shares of the company’s stock, valued at $373,314.15. This represents a 68.53% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mary T. Szela purchased 39,682 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $2.59 per share, with a total value of $102,776.38. Following the acquisition, the chief executive officer owned 1,065,215 shares in the company, valued at $2,758,906.85. This trade represents a 3.87% increase in their position. The disclosure for this purchase is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders bought 719,682 shares of company stock valued at $1,804,176 over the last quarter. 16.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TLSI. Goldman Sachs Group Inc. bought a new position in TriSalus Life Sciences in the first quarter valued at about $187,000. Geode Capital Management LLC raised its stake in TriSalus Life Sciences by 107.4% during the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after acquiring an additional 235,627 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of TriSalus Life Sciences in the second quarter worth about $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $47,000. 2.58% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on TLSI shares. Weiss Ratings cut shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Lake Street Capital cut their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, TriSalus Life Sciences has a consensus rating of “Hold” and an average target price of $7.50.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.